Yen Tzu-Chen, See Lai-Chu, Lai Chyong-Huey, Yah-Huei Chou Wu, Ng Koon-Kwan, Ma Shih-Ya, Lin Wuu-Jyh, Chen Jenn-Tzong, Chen Wen-Jie, Lai Chiung-Ru, Hsueh Swei
Department of Nuclear Medicine, Chang Gung Memorial Hospital and Chang Gung University, Taoyuan, Taiwan.
J Nucl Med. 2004 Jan;45(1):22-9.
This prospective study investigates the relationship between glucose transporter-1 (Glut-1) expression and PET images using (18)F-FDG and its uptake and compares them with the tumor status (primary vs. recurrent or persistent), initial grade of histologic differentiation, and International Federation of Gynecologic Obstetrics (FIGO) staging for cervical cancer patients.
A dual-phase (18)F-FDG PET scan was performed on 51 participants within the 2 wk before surgery or biopsy. (18)F-FDG uptake was quantified by calculating standardized uptake values (SUVs). After (18)F-FDG PET scanning, 51 histologically proven squamous cell carcinoma specimens were examined to determine their degree of differentiation, using hematoxylin and eosin staining, and the expression of Glut-1 by an immunohistochemical stain. Twenty normal cervical and 20 cervical intraepithelial neoplasia (CIN) sets of tissue were also used to compare the results of Glut-1 expression in these tissues. The expression of Glut-1 was the product of (the intensity [with grades 0-3, defined qualitatively]) with (percentages of the lesion area that were positive). The results of Glut-1 expression were analyzed in combination with the SUVs (SUV1 was that at 40 min and SUV2 was that at 3 h), tumor status, initial cell differentiation, and FIGO staging.
Significant overexpression of Glut-1 was noted in 48 of the 51 (94.1%) cancer specimens. None or only minimal expression of Glut-1 was observed in basal layers of normal and CIN tissues. Significant positive correlation was observed between Glut-1 expression and the SUVs in cervical cancer specimens (r = 0.74, P < 0.000 for SUV1 and r = 0.65, P < 0.000 for SUV2). In recurrent or persistent tumor, tumor size was significantly associated with both Glut-1 expression (r = 0.508, P = 0.011) and SUV1 (r = 0. 456, P = 0.025). For recurrent or persistent tumor, only SUV1 reached statistical significance when compared with lymph node metastasis (P = 0.0226).
Glut-1 expression was related to (18)F-FDG uptake in cervical cancer patients. Recurrent or persistent cervical cancer tumor had significantly higher Glut-1 expression than metastatic lymph nodes. The values of SUV and the expression of Glut-1 did not correlate with the initial grade of histologic differentiation and FIGO staging.
本前瞻性研究调查了葡萄糖转运蛋白1（Glut-1）表达与使用（18）F-FDG的PET图像及其摄取之间的关系，并将它们与宫颈癌患者的肿瘤状态（原发性与复发性或持续性）、初始组织学分化程度以及国际妇产科联合会（FIGO）分期进行比较。
在手术或活检前2周内对51名参与者进行了双期（18）F-FDG PET扫描。通过计算标准化摄取值（SUV）对（18）F-FDG摄取进行定量。在（18）F-FDG PET扫描后，对51个经组织学证实的鳞状细胞癌标本进行检查，使用苏木精和伊红染色确定其分化程度，并通过免疫组织化学染色确定Glut-1的表达。还使用20例正常宫颈组织和20例宫颈上皮内瘤变（CIN）组织来比较这些组织中Glut-1表达的结果。Glut-1的表达是（强度[定性定义为0-3级]）与（病变区域阳性的百分比）的乘积。结合SUV（SUV1为40分钟时的值，SUV2为3小时时的值）、肿瘤状态、初始细胞分化和FIGO分期对Glut-1表达结果进行分析。
51个癌症标本中有48个（94.1%）观察到Glut-1明显过表达。在正常组织和CIN组织的基底层未观察到Glut-1表达或仅观察到极少表达。在宫颈癌标本中，Glut-1表达与SUV之间观察到显著正相关（SUV1时r = 0.74，P < 0.000；SUV2时r = 0.65，P < 0.000）。在复发性或持续性肿瘤中，肿瘤大小与Glut-1表达（r = 0.508，P = 0.011）和SUV1（r = 0.456，P = 0.025）均显著相关。对于复发性或持续性肿瘤，与淋巴结转移相比，仅SUV1达到统计学显著性（P = 0.0226）。
Glut-1表达与宫颈癌患者的（18）F-FDG摄取有关。复发性或持续性宫颈癌肿瘤的Glut-1表达明显高于转移性淋巴结。SUV值和Glut-1表达与初始组织学分化程度和FIGO分期无关。
